Clinical Trials in Esplugues, Barcelona
8 recruiting
Showing 1–8 of 8 trials
Recruiting
Phase 2Phase 3
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
Lymphatic Malformations
Novartis Pharmaceuticals232 enrolled55 locationsNCT05948943
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma
Asthma
Novartis Pharmaceuticals200 enrolled62 locationsNCT05562466
Recruiting
Phase 3
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up
Chronic Spontaneous Urticaria
Novartis Pharmaceuticals100 enrolled65 locationsNCT05677451
Recruiting
Phase 2
EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)
PIK3CA-Related Overgrowth Spectrum (PROS)
Novartis Pharmaceuticals104 enrolled30 locationsNCT06997588
Recruiting
Phase 2
A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease
Still´s Disease
Novartis Pharmaceuticals20 enrolled22 locationsNCT07203001
Recruiting
Phase 2
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asthma
Asthma
Novartis Pharmaceuticals42 enrolled23 locationsNCT05222529
Recruiting
Phase 3
Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia
Familial Hypercholesterolemia - Heterozygous
Novartis Pharmaceuticals51 enrolled66 locationsNCT06597019
Recruiting
Phase 3
CAR-T Long Term Follow Up (LTFU) Study
Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program
Novartis Pharmaceuticals1,400 enrolled118 locationsNCT02445222